Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Valneva's Ixchiq is the first and only approved Chikungunya vaccine in the US, Canada, and EU. Ixiaro is for Japanese encephalitis, and it’s today VALN’s main revenue contributor. But its near ...

Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Bavarian Nordic is now catching up to Valneva, whose Ixchiq vaccine became the world’s first licensed chikungunya vaccine when it was approved by the US Food and Drug Administration (FDA) in November ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

for the world’s first and only chikungunya vaccine, IXCHIQ ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV ...

for the world’s first and only chikungunya vaccine, Ixchiq. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in ...